ArticleJPEN. Journal of parenteral and enteral nutrition2016
Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness.
Article in JPEN. Journal of parenteral and enteral nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- IntravenousJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Anti-inflammatory effects ofScientific reports · 2025Article
- Zinc Deficiency and Zinc Supplementation in Allergic Diseases.Biomolecules · 2024Review
- Explorations on the antiviral potential of zinc and magnesium salts against chikungunya virus: implications for therapeutics.Frontiers in cellular and infection microbiology · 2024Article
- The Anti-Oxidative, Anti-Inflammatory, Anti-Apoptotic, and Anti-Necroptotic Role of Zinc in COVID-19 and Sepsis.Antioxidants (Basel, Switzerland) · 2023Review
- Mesoporous Silica Modified with Polydopamine and Zinc Ions as a Potential Carrier in the Controlled Release of Mercaptopurine.Materials (Basel, Switzerland) · 2023Article
- Article
- Ionic mitigation of CD4Scientific reports · 2022Article
- Zinc as a Drug for Wilson's Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury.Molecules (Basel, Switzerland) · 2021Review
- Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities.British journal of clinical pharmacology · 2021Review
- Article
- Micronutrient status during paediatric critical illness: A scoping review.Clinical nutrition (Edinburgh, Scotland) · 2020Article
- Nutritional support for children during critical illness: European Society of Pediatric and Neonatal Intensive Care (ESPNIC) metabolism, endocrine and nutrition section position statement and clinical recommendations.Intensive care medicine · 2020Review
- Assessment of Micronutrient Status in Critically Ill Children: Challenges and Opportunities.Nutrients · 2017Review
- Copper to Zinc Ratio as Disease Biomarker in Neonates with Early-Onset Congenital Infections.Nutrients · 2017Observational
- Zinc supplementation leads to immune modulation and improved survival in a juvenile model of murine sepsis.Innate immunity · 2017Article
- Effects of maternal mild zinc deficiency and different ways of zinc supplementation for offspring on learning and memory.Food & nutrition research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCritically ill children have low plasma zinc (pZn), correlating with organ failure. Since Zn influences inflammation, immune function, and glucose control, Zn supplementation is a plausible therapeutic modality. We sought to determine a safe dose of intravenous (IV) Zn to restore pZn in critically ill children.
methodsStepwise dose escalation study of IV Zn supplementation at a tertiary children's hospital. All children (<10 years) admitted to the pediatric intensive care unit with a Pediatric Risk of Mortality III score >5, or ≥1 new organ failure were eligible. After consent, patients were sequentially enrolled into 4 dosing groups: (1) no zinc, (2) Zn250: 250 mcg/kg/d ZnSO4, (3) Zn500: 500 mcg/kg/d ZnSO4, or (4) Zn750: 750 mcg/kg/d ZnSO4 ZnSO4 was administered 3 times daily for 7 days. pZn was measured at baseline, end of first ZnSO4 infusion, 1 hour postinfusion, and 7 hours postinfusion on day 1, then daily through days 2-7. Interleukin-6 (IL-6), C-reactive protein (CRP), and lymphocyte subsets were measured on days 1 and 3. Glucose was measured 3 times daily for 7 days.
resultsTwenty-four patients were enrolled. Baseline demographics were similar among groups. Baseline pZn was low in all patients (mean [SD], 41.8 [16.0] mcg/dL). pZn increased over the study period in supplemented groups; however, mean pZn in the Zn750 group exceeded the 50th percentile. pZn was not associated with IL-6, CRP, or lymphocyte subsets among groups. Degree of hyperglycemia did not differ among groups. No patient had a study-related adverse event.
conclusionsIV zinc supplementation at 500 mcg/kg/d restores pZn to near the 50th percentile and is well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.